

#### **Issuance & Disclosure Department**

# Preliminary Results of Public Joint Shareholders Company (Final Result Brief for the year ended 31/12/2017)

## **First - General Information:**

Name of the company: Gulf Pharmaceutical Industries (JULPHAR)

**Date Establishment: 1980** 

Paid up capital: 1,124,760,000/-

**Subscribed capital: 1,124,760,000/-**

**Authorized capital: 1,124,760,000/-**

Chairman of the Board: SH.Faisal Bin Saqr Al Qasimi

General Manager: Jerome Carle

Name of the external auditor: M/S. PWC.

Mailing address: P.O.Box: 997

Tel: 009717 2461461

Fax: 0097172462462

E - Mail: hanan.horani@julphar.net

#### **Second - Preliminary Results (000 AED):**

	2016	2017
1. Total Assets	3,450,743	3,527,700
2. Shareholders' Equity	2,306,066	2,210,400
3. Revenues	1,454,532	1,273,400
4. Net Operating Profit	229,227	110,900
5. Net profit for the period	210,027	90,300
6. Earnings per share	19	8.4

## 7- Summary of the company's performance for the last fiscal year.

During 2017 Julphar registered consolidated revenue of AED 1,273.4 million, which was 12.5% lower than 2016, consolidated net profit reached AED 90.3 million, lower by 57.0% compared to the year 2016. Julphar operations have been impacted by currency headwinds (devaluation of Egypt, Ethiopia, Algeria and Sudan currencies), Forex shortage (Libya and Ethiopia), political instability (Yemen, Syria and Afghanistan), price reductions (GCC) and restrictions on import licenses (Algeria and Qatar).

Chairman or authorized person signature:....

Company stamp:

